Stifel Financial Corp Invests $199,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Stifel Financial Corp acquired a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,746 shares of the company’s stock, valued at approximately $199,000.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals during the third quarter valued at approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares during the last quarter. Principal Financial Group Inc. bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter worth $87,000. Quarry LP acquired a new position in shares of ARS Pharmaceuticals in the 3rd quarter worth $174,000. Finally, TFG Advisers LLC acquired a new stake in shares of ARS Pharmaceuticals during the third quarter worth $180,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Insider Transactions at ARS Pharmaceuticals

In other news, Director Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at $2,892,257.50. The trade was a 6.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total value of $1,488,000.00. Following the completion of the sale, the insider now directly owns 1,298,499 shares of the company’s stock, valued at approximately $19,321,665.12. The trade was a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,258,058 shares of company stock valued at $19,369,686 over the last three months. 40.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SPRY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Leerink Partners raised their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $24.00.

ARS Pharmaceuticals Trading Down 1.6 %

Shares of ARS Pharmaceuticals stock opened at $10.62 on Tuesday. ARS Pharmaceuticals, Inc. has a 1 year low of $5.19 and a 1 year high of $18.51. The company has a market cap of $1.03 billion, a P/E ratio of -20.82 and a beta of 0.88. The stock has a 50-day moving average price of $13.91 and a 200 day moving average price of $12.56.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.